CS145091A3 - Isoxazole-4-carboxamides and amides of hydroxyalkylidene cyanacetic acid, medicaments comprising said compounds and their application - Google Patents

Isoxazole-4-carboxamides and amides of hydroxyalkylidene cyanacetic acid, medicaments comprising said compounds and their application

Info

Publication number: CS145091A3
Authority: CS; Czechoslovakia
Prior art keywords: compounds; isoxazole; hydroxyalkylidene; carboxamides; medicaments
Prior art date: 1990-05-18

Application number

CS911450A

Other languages

English (en)

Inventor

Robert R Dr Bartlett

Friedrich-Johannes Dr Kammerer

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-18

Filing date

1991-05-16

Publication date

1992-01-15

1991-05-16 Application filed by Hoechst Ag filed Critical Hoechst Ag

1992-01-15 Publication of CS145091A3 publication Critical patent/CS145091A3/cs

2002-07-17 Publication of CZ290474B6 publication Critical patent/CZ290474B6/cs

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Hydrogenated Pyridines (AREA)
Thiazole And Isothizaole Compounds (AREA)
Air Conditioning Control Device (AREA)
Photoreceptors In Electrophotography (AREA)
Medicinal Preparation (AREA)
Indole Compounds (AREA)

CS19911450A 1990-05-18 1991-05-16 Isoxazol-4-karboxamidy, způsob jejich výroby, farmaceutický prostředek tyto sloučeniny obsahující a jejich pouľití CZ290474B6 (cs)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE4016178		1990-05-18
DE4017043		1990-05-26
DE4017020		1990-05-26

Publications (2)

Publication Number	Publication Date
CS145091A3 true CS145091A3 (en)	1992-01-15
CZ290474B6 CZ290474B6 (cs)	2002-07-17

Family

ID=27201216

Country Status (28)

Country	Link
US (2)	US5494911A (cs)
EP (1)	EP0527736B1 (cs)
JP (3)	JP2995086B2 (cs)
KR (1)	KR100188801B1 (cs)
CN (1)	CN1051074C (cs)
AT (1)	ATE151633T1 (cs)
AU (2)	AU649421B2 (cs)
BR (1)	BR9008022A (cs)
CA (1)	CA2083179C (cs)
CY (1)	CY2123B1 (cs)
CZ (4)	CZ290474B6 (cs)
DE (1)	DE59010701D1 (cs)
DK (1)	DK0527736T3 (cs)
ES (1)	ES2102367T3 (cs)
FI (1)	FI105683B (cs)
GR (1)	GR3023638T3 (cs)
HU (1)	HU222234B1 (cs)
IE (1)	IE911694A1 (cs)
IL (1)	IL98163A (cs)
LV (1)	LV10575B (cs)
NO (1)	NO180118C (cs)
NZ (1)	NZ238165A (cs)
PT (1)	PT97689B (cs)
RU (2)	RU2084223C1 (cs)
SK (3)	SK281317B6 (cs)
TW (2)	TW211558B (cs)
WO (1)	WO1991017748A1 (cs)
YU (1)	YU48765B (cs)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ235563A (en) *	1989-10-13	1993-04-28	Merck & Co Inc	Fibrinogen receptor antagonist and pharmaceutical composition
GB9200275D0 (en) *	1992-01-08	1992-02-26	Roussel Lab Ltd	Chemical compounds
GB9300083D0 (en) *	1993-01-05	1993-03-03	Roussel Lab Ltd	Chemical compounds
ATE174219T1 (de) *	1993-01-08	1998-12-15	Hoechst Ag	Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
ATE174220T1 (de) *	1993-01-08	1998-12-15	Hoechst Ag	Verwendung von leflunomid zur hemmung von interleukin 8
ES2124800T3 (es) *	1993-01-08	1999-02-16	Hoechst Ag	Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
EP0607774B1 (de) *	1993-01-08	1998-12-09	Hoechst Aktiengesellschaft	Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
TW314467B (cs) *	1993-03-31	1997-09-01	Hoechst Ag
GB9313365D0 (en) *	1993-06-29	1993-08-11	Roussel Lab Ltd	Chemical compounds
DE4323636A1 (de) *	1993-07-15	1995-01-19	Hoechst Ag	Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
GB9322781D0 (en) *	1993-11-04	1993-12-22	Roussel Lab Ltd	Aromatic amides
US6335356B1 (en)	1994-01-07	2002-01-01	Sugen, Inc.	Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) *	1994-01-07	1997-03-11	Sugen, Inc.	Formulations for lipophilic compounds
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
US5721277A (en) *	1995-04-21	1998-02-24	Sugen, Inc.	Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en)	1995-06-01	2001-12-18	University Of California	Treatment of platelet derived growth factor related disorders such as cancers
GB9520092D0 (en) *	1995-10-02	1995-12-06	Hoechst Roussel Ltd	Chemical compounds
DE19539638A1 (de) *	1995-10-25	1997-04-30	Hoechst Ag	Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19547648A1 (de) *	1995-12-20	1997-06-26	Hoechst Ag	Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
ES2257756T3 (es) *	1996-03-12	2006-08-01	Sanofi-Aventis Deutschland Gmbh	Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.
DE19610955A1 (de)	1996-03-20	1997-09-25	Hoechst Ag	Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
US6011051A (en) *	1996-07-31	2000-01-04	Hoechst Aktiengesellschaft	Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
IL128642A0 (en)	1996-09-04	2000-01-31	Pfizer	Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
DE19702988A1 (de) *	1997-01-28	1998-07-30	Hoechst Ag	Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
EP1012150A4 (en) *	1997-05-19	2002-05-29	Sugen Inc	HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
US6316479B1 (en) *	1997-05-19	2001-11-13	Sugen, Inc.	Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
EP0903345B1 (de) *	1997-08-08	2000-10-04	Aventis Pharma Deutschland GmbH	Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
EA200000385A1 (ru) *	1997-11-04	2000-10-30	Пфайзер Продактс Инк.	Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4)
HUP0102661A2 (hu) *	1998-04-17	2001-11-28	Parker Hughes Institute	BTK-inhibitorok és a BTK-inhibitorok azonosítására szolgáló eljárások, valamint alkalmazásuk
US6303652B1 (en)	1998-08-21	2001-10-16	Hughes Institute	BTK inhibitors and methods for their identification and use
US6355678B1 (en) *	1998-06-29	2002-03-12	Parker Hughes Institute	Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DE19908527C2 (de) *	1999-02-26	2001-08-30	Aventis Pharma Gmbh	Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
AU779931B2 (en) *	1999-12-16	2005-02-17	Teva Pharmaceutical Industries Ltd.	Novel processes for making- and a new crystalline form of- leflunomide
US7217722B2 (en)	2000-02-01	2007-05-15	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
ES2237553T3 (es) *	2000-02-15	2005-08-01	Teva Pharmaceutical Industries Ltd.	Procedimiento para la sintesis de leflunomida.
US20030055263A1 (en) *	2001-07-11	2003-03-20	Boehringer Ingelheim Pharma Kg	Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
DE10133665A1 (de) *	2001-07-11	2003-01-30	Boehringer Ingelheim Pharma	Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US6858637B2 (en)	2002-03-28	2005-02-22	Neurogen Corporation	Substituted biaryl amides as C5a receptor modulators
CA2479928A1 (en) *	2002-03-28	2003-10-09	Neurogen Corporation	Substituted biaryl amides as c5a receptor modulators
JP2006505571A (ja) *	2002-10-15	2006-02-16	リゲルファーマシューテイカルズ、インコーポレイテッド	置換されたインドール及びｈｃｖ阻害剤としてのその使用
CN101006065B (zh)	2004-06-17	2012-07-11	英菲尼蒂发现公司	抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
US7842815B2 (en)	2004-06-17	2010-11-30	Infinity Pharmaceuticals, Inc.	Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20110104186A1 (en)	2004-06-24	2011-05-05	Nicholas Valiante	Small molecule immunopotentiators and assays for their detection
DE102006014165A1 (de) *	2006-03-24	2007-09-27	Schebo Biotech Ag	Neue Isooxazol-Derivate und deren Verwendungen
AU2007275301A1 (en) *	2006-07-20	2008-01-24	Amgen Inc.	Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
TWI389895B (zh)	2006-08-21	2013-03-21	Infinity Discovery Inc	抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
GEP20125379B (en) *	2007-05-03	2012-01-10	Pfizer Ltd	2 -pyridine carboxamide derivatives as sodium channel modulators
US20090076275A1 (en) *	2007-09-19	2009-03-19	David Robert Bolin	Diacylglycerol acyltransferase inhibitors
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
AU2009329917B2 (en)	2008-12-23	2016-03-31	Gilead Pharmasset Llc	Nucleoside analogs
SG194404A1 (en)	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Synthesis of purine nucleosides
AR074897A1 (es) *	2008-12-23	2011-02-23	Pharmasset Inc	Fosforamidatos de nucleosidos
MY159575A (en)	2009-04-02	2017-01-13	Merck Serono Sa	Dihydroorotate dehydrogenase inhibitors
EP2236505A1 (de) *	2009-04-03	2010-10-06	Bayer CropScience AG	Acylierte Aminopyridine und - pyridazine als Insektizide
EP2451773A2 (en)	2009-07-09	2012-05-16	Alembic Pharmaceuticals Limited	Novel polymorphic form of teriflunomide salts
PT2609923T (pt)	2010-03-31	2017-08-30	Gilead Pharmasset Llc	Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
EP2608782B1 (en)	2010-08-24	2016-06-29	Algiax Pharmaceuticals GmbH	Novel use of leflunomide and malononitrilamides
SI2632451T1 (en)	2010-10-29	2018-02-28	Algiax Pharmaceuticals Gmbh	Use of malononitrilamides in neuropathic pain
WO2012110911A1 (en)	2011-02-18	2012-08-23	Alembic Pharmaceuticals Limited	Novel polymorphic form of teriflunomide
US20140038967A1 (en)	2011-03-17	2014-02-06	Algiax Pharmaceuticals Gmbh	Novel use for imidazotriazinones
WO2012123353A1 (en)	2011-03-17	2012-09-20	Algiax Pharmaceuticals Gmbh	Novel use of benzofuranylsulfonates
HUE042032T2 (hu)	2013-02-25	2019-06-28	Aurigene Discovery Tech Ltd	Triszubsztituált benzotriazol-származékok, melyek dihidro-orotát-oxigenáz-inhibitor hatásúak
WO2015029063A2 (en) *	2013-08-30	2015-03-05	Msn Laboratories Private Limited	Novel polymorph of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4-trifluoromethyl phenyl)-amide and process for the preparation thereof
AU2014352920A1 (en)	2013-11-22	2016-06-23	Genzyme Corporation	Novel methods for treating neurodegenerative diseases
AU2015205374B2 (en)	2014-01-13	2018-08-23	Aurigene Oncology Limited	Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
WO2015193846A1 (en) *	2014-06-20	2015-12-23	Aurigene Discovery Technologies Limited	Substituted indazole compounds as irak4 inhibitors
CN105272882B (zh) *	2014-07-23	2019-05-31	欣凯医药化工中间体（上海）有限公司	一种环保简便制备泰瑞米特的方法
KR102719583B1 (ko) *	2015-06-17	2024-10-18	바이오콘 리미티드	테리플루노미드의 신규한 제조 공정
BR112019017567A2 (pt)	2017-02-24	2020-03-24	Merck Patent Gmbh	Derivados de 1,4,6-trissubstituído-2-alquil-1h-benzo[d]imidazol como inibidores da di-hidro-orotato oxigenase
FI3600270T3 (fi)	2017-03-31	2023-07-20	Aurigene Oncology Ltd	Yhdisteitä ja koostumuksia hematologisten häiriöiden hoitoon
HUE056485T2 (hu)	2017-04-24	2022-02-28	Aurigene Discovery Tech Ltd	Eljárások háromszorosan szubsztituált benzotriazol-származékok alkalmazására dihidroorotát-oxigenáz inhibitorokként
US20180369206A1 (en)	2017-04-24	2018-12-27	Aurigene Discovery Technologies Limited	Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
RS65572B1 (sr)	2017-10-31	2024-06-28	Curis Inc	Inhibitor irak4 u kombinaciji sa inhibitorom bcl-2 za upotrebu u lečenju kancera
TR202022336A2 (tr)	2020-12-30	2022-07-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A film coated tablet comprising teriflunomide
BR112023020669A2 (pt)	2021-04-08	2023-12-12	Curis Inc	Terapias de combinação para o tratamento de câncer
EP4162933A1 (en)	2021-10-08	2023-04-12	Algiax Pharmaceuticals GmbH	Compound for treating non-alcoholic fatty liver disease and related diseases
EP4382097A1 (en)	2022-11-25	2024-06-12	Sanovel Ilac Sanayi Ve Ticaret A.S.	A tablet comprising teriflunomide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2524959C2 (de) *	1975-06-05	1983-02-10	Hoechst Ag, 6000 Frankfurt	5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
ES448386A1 (es) *	1975-06-05	1978-04-16	Hoechst Ag	Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
NL186239B (nl) *	1975-06-05		Hoechst Ag	Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2557003A1 (de) *	1975-12-18	1977-06-23	Hoechst Ag	Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2555789A1 (de) *	1975-12-11	1977-07-07	Hoechst Ag	Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2655009A1 (de) *	1976-12-04	1978-06-15	Hoechst Ag	Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2854439A1 (de) *	1978-12-16	1980-07-03	Hoechst Ag	Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3405727A1 (de) *	1984-02-17	1985-08-22	Hoechst Ag, 6230 Frankfurt	Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3534440A1 (de) *	1985-09-27	1987-04-02	Hoechst Ag	Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619433D0 (en) *	1986-08-08	1986-09-17	Lilly Industries Ltd	Pharmaceutical compounds
GB8619432D0 (en) *	1986-08-08	1986-09-17	Lilly Industries Ltd	Pharmaceutical compounds
US4816467A (en) *	1987-01-09	1989-03-28	Farmitalia Carlo Erba S.R.L	Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use

1990
- 1990-10-24 DK DK90915462.7T patent/DK0527736T3/da active
- 1990-10-24 WO PCT/EP1990/001800 patent/WO1991017748A1/de active IP Right Grant
- 1990-10-24 HU HU9203619A patent/HU222234B1/hu active IP Right Grant
- 1990-10-24 RU RU9092016445A patent/RU2084223C1/ru active
- 1990-10-24 RU RU94033835A patent/RU2142937C1/ru active
- 1990-10-24 JP JP2514415A patent/JP2995086B2/ja not_active Expired - Lifetime
- 1990-10-24 CA CA002083179A patent/CA2083179C/en not_active Expired - Lifetime
- 1990-10-24 AT AT90915462T patent/ATE151633T1/de not_active IP Right Cessation
- 1990-10-24 AU AU65468/90A patent/AU649421B2/en not_active Expired
- 1990-10-24 DE DE59010701T patent/DE59010701D1/de not_active Expired - Lifetime
- 1990-10-24 BR BR909008022A patent/BR9008022A/pt not_active Application Discontinuation
- 1990-10-24 KR KR1019920702895A patent/KR100188801B1/ko not_active IP Right Cessation
- 1990-10-24 EP EP90915462A patent/EP0527736B1/de not_active Expired - Lifetime
- 1990-10-24 ES ES90915462T patent/ES2102367T3/es not_active Expired - Lifetime
- 1990-10-24 US US07/938,048 patent/US5494911A/en not_active Expired - Lifetime
- 1990-10-27 TW TW081101406A patent/TW211558B/zh active
- 1990-10-27 TW TW079109110A patent/TW205004B/zh active
1991
- 1991-05-16 CN CN91103182A patent/CN1051074C/zh not_active Expired - Lifetime
- 1991-05-16 SK SK1376-98A patent/SK281317B6/sk not_active IP Right Cessation
- 1991-05-16 PT PT97689A patent/PT97689B/pt not_active IP Right Cessation
- 1991-05-16 NZ NZ238165A patent/NZ238165A/en not_active IP Right Cessation
- 1991-05-16 SK SK542-99A patent/SK281318B6/sk not_active IP Right Cessation
- 1991-05-16 SK SK1450-91A patent/SK281316B6/sk not_active IP Right Cessation
- 1991-05-16 IL IL9816391A patent/IL98163A/en not_active IP Right Cessation
- 1991-05-16 CZ CS19911450A patent/CZ290474B6/cs not_active IP Right Cessation
- 1991-05-17 IE IE169491A patent/IE911694A1/en not_active IP Right Cessation
- 1991-05-20 YU YU88491A patent/YU48765B/sr unknown
1992
- 1992-11-17 NO NO924433A patent/NO180118C/no not_active IP Right Cessation
- 1992-11-17 FI FI925211A patent/FI105683B/fi active
1993
- 1993-05-07 LV LVP-93-310A patent/LV10575B/en unknown
1994
- 1994-03-23 AU AU57992/94A patent/AU662465B2/en not_active Expired
1995
- 1995-06-07 US US08/476,278 patent/US5532259A/en not_active Expired - Lifetime
- 1995-08-24 CZ CZ19952176A patent/CZ290717B6/cs not_active IP Right Cessation
- 1995-11-23 CZ CZ19953092A patent/CZ290737B6/cs not_active IP Right Cessation
- 1995-11-23 CZ CZ19953091A patent/CZ290736B6/cs not_active IP Right Cessation
1997
- 1997-05-30 GR GR970401284T patent/GR3023638T3/el unknown
1998
- 1998-09-29 CY CY9800032A patent/CY2123B1/xx unknown
1999
- 1999-03-01 JP JP05210799A patent/JP3201747B2/ja not_active Expired - Lifetime
- 1999-03-01 JP JP05210899A patent/JP3233610B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
KR100188801B1 (ko)	1999-06-01
BR9008022A (pt)	1993-04-06
ATE151633T1 (de)	1997-05-15
AU5799294A (en)	1994-07-07
TW205004B (cs)	1993-05-01
SK281317B6 (sk)	2001-02-12
JP3233610B2 (ja)	2001-11-26
FI925211A (fi)	1992-11-17
RU94033835A (ru)	1996-04-20
CN1056684A (zh)	1991-12-04
NO180118B (no)	1996-11-11
SK281318B6 (sk)	2001-02-12
NO180118C (no)	1997-02-19
NO924433D0 (no)	1992-11-17
GR3023638T3 (en)	1997-08-29
IL98163A (en)	1996-01-31
JP2995086B2 (ja)	1999-12-27
NZ238165A (en)	1994-08-26
NO924433L (no)	1992-11-17
IE911694A1 (en)	1991-11-20
CA2083179C (en)	2001-10-23
AU6546890A (en)	1991-12-10
YU88491A (sh)	1995-03-27
CA2083179A1 (en)	1991-11-19
LV10575B (en)	1996-04-20
AU649421B2 (en)	1994-05-26
EP0527736B1 (de)	1997-04-16
JPH11322700A (ja)	1999-11-24
PT97689B (pt)	1998-09-30
ES2102367T3 (es)	1997-08-01
EP0527736A1 (de)	1993-02-24
WO1991017748A1 (de)	1991-11-28
HUT64314A (en)	1993-12-28
FI105683B (fi)	2000-09-29
CZ290737B6 (cs)	2002-10-16
DE59010701D1 (de)	1997-05-22
YU48765B (en)	1999-11-22
CZ290717B6 (cs)	2002-10-16
US5532259A (en)	1996-07-02
DK0527736T3 (da)	1997-10-20
IL98163A0 (en)	1992-06-21
HU222234B1 (hu)	2003-05-28
PT97689A (pt)	1992-02-28
CY2123B1 (en)	2002-06-21
JP3201747B2 (ja)	2001-08-27
TW211558B (cs)	1993-08-21
JPH11343285A (ja)	1999-12-14
CZ290736B6 (cs)	2002-10-16
HU9203619D0 (en)	1993-03-29
JPH05506425A (ja)	1993-09-22
RU2084223C1 (ru)	1997-07-20
AU662465B2 (en)	1995-08-31
RU2142937C1 (ru)	1999-12-20
FI925211A0 (fi)	1992-11-17
SK281316B6 (sk)	2001-02-12
US5494911A (en)	1996-02-27
CZ290474B6 (cs)	2002-07-17
CN1051074C (zh)	2000-04-05
LV10575A (lv)	1995-04-20

Publication	Publication Date	Title
CS145091A3 (en)	1992-01-15	Isoxazole-4-carboxamides and amides of hydroxyalkylidene cyanacetic acid, medicaments comprising said compounds and their application
TR199801180T2 (xx)	1998-10-21	Aneljestik etkiye sahip yeni bile�ikler.
IS3156A7 (is)	1987-04-30	Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
MY110110A (en)	1998-01-27	Pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and cns disorders
HU9502174D0 (en)	1995-09-28	Aminoacid derivatives, medicaments containing these compounds and process for preparing the same
DK0506539T3 (da)	1997-12-01	heterocykliske alkylamider, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
NZ233735A (en)	1992-10-28	Heterocyclic substituted aminophenol derivatives
YU211087A (en)	1988-12-31	Process for obtaining new n-substituted benzimidazolic derivatives
ES8402261A1 (es)	1984-01-16	Procedimiento para la obtencion de nuevos derivados de omega-ciano-1,omega difenil-aza-alcano.
DE69414194D1 (de)	1998-12-03	Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren
TR199801184T2 (xx)	1998-09-21	Analjezik tesirli yeni bile�ikler.
ES8304975A1 (es)	1983-03-16	"procedimiento para la preparacion de derivados triptaminicos sustituidos de tieniloxipropanolaminas, racemicos y opticamente activos".
GR3015132T3 (en)	1995-05-31	Novel ureas and thioureas, preparation thereof and application in therapy.
DE69321096D1 (de)	1998-10-22	Katecholamine-diphosphate und diese enthaltende arzneimittel
ES464595A1 (es)	1978-09-01	Procedimiento de preparacion de nuevos derivados de fenotia-zina.

Legal Events

Date	Code	Title	Description
2000-06-30	PD00	Pending as of 2000-06-30 in czech republic
2011-05-25	MK4A	Patent expired	Effective date: 20110516